
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a leader in the diabetes technology market, recognized for their innovative and comprehensive product offerings. With a strong focus on glucose control and a promising product pipeline, analysts have set a $25 price target for the company. Their global presence and unique market position make them a solid investment in the growing MedTech industry.
Bears say
Minimed Group is facing intense competition in the diabetes medical technology industry, with multiple companies offering similar products and solutions. While they have clear differentiation and early clinical data, it will be crucial for the company to execute successfully on its new product launches to stay competitive. MiniMed has shown effective execution on its regulatory approval plans and timelines, but approvals and timely launches remain a risk. Additionally, reimbursement access is increasing, but out-of-pocket costs and workflow/technology burden may still be barriers for patients.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares